Market By Device Type, Route Of Administration, End-user, And Country | Forecast 2019-2028
The Asia-Pacific injectable drug delivery market is expected to make progress at a CAGR of 9.66% in terms of revenue throughout the estimated period 2019-2028.
The countries studied in this market include:
• India
• Japan
• China
• Australia & New Zealand
• ASEAN countries
• South Korea
• Rest of APAC countries
The Chinese drug delivery market is primarily being driven by the growing prevalence of cancer, an increase in the number of hospitals, the need to deliver better-quality healthcare services, and the increasing focus to boost the biologics sector. Cancer nanoparticle-based drug delivery systems show immense potential as a mode of cancer treatment. The rising number of cancer cases is, therefore, raising the demand for these systems. This increased demand, in turn, is fuelling China’s injectable drug delivery market growth over the forecast period.
Also, the data from 2016 WHO studies suggest that the percentage of R&D investments in top Chinese firms reached 5% of the total revenues. And the highest percentage of this expenditure was contributed to by the biologics sector. For instance, Suzhou’s Innovent Biologics, based in China, collaborated with Eli Lily and Company, raising approx. $450 million for commercializing three new cancer treatments. The increasing expenditure on biologics is aiding the companies’ R&D teams to develop novel drug delivery technologies. These factors are enhancing the adoption of injectable drug delivery technologies in China, which is expected to favor its market growth.
In Australia, the number of cancer patients is expected to rise by a staggering 17,000 people, in the three year period from 2017-2020. Nanoparticles, which are a crucial element of nanomedicines, have garnered special interest, as they are being looked upon as promising drug delivery systems for cancer treatment. Therefore, the growing number of cancer patients in the country is helping the growth of the studied market in Australia over the forecasting period.
Established in 1921, Terumo Corporation is a company that is engaged in the design, manufacture, and commercialization of medical products and equipment. PLAJEX, one of the products offered by the company, consists of prefillable syringes with staked needles. Terumo is headquartered in Tokyo, Japan. The company invests heavily in R&D as it believes in continuous innovation to maintain its leading position in the industry.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. PORTER’S FIVE FORCES MODEL
2.2.1. THREAT OF NEW ENTRANT
2.2.2. THREAT OF SUBSTITUTE
2.2.3. BARGAINING POWER OF BUYERS
2.2.4. BARGAINING POWER OF SUPPLIERS
2.2.5. INTENSITY OF COMPETITIVE RIVALRY
2.3. KEY INSIGHT
2.4. KEY BUYING CRITERIA
2.5. MARKET ATTRACTIVENESS INDEX
2.6. MARKET DRIVERS
2.6.1. INCREASING GERIATRIC POPULATION
2.6.2. TECHNOLOGICAL ADVANCEMENT
2.6.3. GROWING OCCURRENCE OF AUTOIMMUNE DISEASES
2.7. MARKET RESTRAINTS
2.7.1. HIGH MANUFACTURING COST OF INJECTABLE DRUG DELIVERY SYSTEMS
2.8. MARKET OPPORTUNITIES
2.8.1. DEVELOPMENT OF BETTER INJECTABLE SYSTEMS
2.8.2. INCREASE IN HEALTHCARE EXPENDITURE
2.9. MARKET CHALLENGES
2.9.1. DEVELOPMENTS IN ALTERNATE DRUG DELIVERY SYSTEMS
2.9.2. STRINGENT REGULATIONS
3. INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY DEVICE TYPE
3.1. PEN INJECTOR
3.2. AUTO-INJECTOR
3.3. NEEDLE-FREE INJECTOR
3.4. PREFILLED SYRINGE
4. INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY ROUTE OF ADMINISTRATION
4.1. SUBCUTANEOUS
4.2. INTRAMUSCULAR
4.3. INTRAVENOUS (IV)
4.4. OTHER ROUTE OF ADMINISTRATION
5. INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY END-USER
5.1. CLINICS/ PHYSICIAN OFFICES
5.2. AMBULATORY CARE
5.3. HOSPITAL
5.4. HOME-BASED
5.5. OTHER END-USERS
6. INJECTABLE DRUG DELIVERY MARKET – ASIA-PACIFIC
6.1. COUNTRY ANALYSIS
6.1.1. JAPAN
6.1.2. CHINA
6.1.3. AUSTRALIA & NEW ZEALAND
6.1.4. INDIA
6.1.5. SOUTH KOREA
6.1.6. ASEAN COUNTRIES
6.1.7. REST OF ASIA-PACIFIC
7. COMPANY PROFILES
7.1. BAXTER INTERNATIONAL INC
7.2. BECTON DICKINSON AND COMPANY (BD)
7.3. ELCAM MEDICAL
7.4. ELI LILLY AND COMPANY
7.5. GERRESHEIMER
7.6. INJEX
7.7. NOVARTIS AG
7.8. NOVO NORDISK A/S
7.9. PFIZER INC
7.10. SANOFI SA
7.11. SCHOTT AG
7.12. TERUMO CORPORATION
7.13. TEVA PHARMACEUTICALS
7.14. WEST PHARMACEUTICALS
7.15. YPSOMED HOLDING AG
8. RESEARCH METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE & DELIVERABLES
8.1.1. OBJECTIVES OF STUDY
8.1.2. SCOPE OF STUDY
8.2. SOURCES OF DATA
8.2.1. PRIMARY DATA SOURCES
8.2.2. SECONDARY DATA SOURCES
8.3. RESEARCH METHODOLOGY
8.3.1. EVALUATION OF PROPOSED MARKET
8.3.2. IDENTIFICATION OF DATA SOURCES
8.3.3. ASSESSMENT OF MARKET DETERMINANTS
8.3.4. DATA COLLECTION
8.3.5. DATA VALIDATION & ANALYSIS
TABLE 1 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2019-2028 ($ MILLION)
TABLE 2 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2019-2028 ($ MILLION)
TABLE 3 DIFFERENT TYPES OF INSULIN PEN INJECTORS
TABLE 4 MARKETED NEEDLE-FREE INJECTORS PRODUCTS
TABLE 5 LYOPHILIZED DRUGS WHICH ARE USED IN PREFILLED SYRINGE
TABLE 6 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)
TABLE 7 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY END-USER, 2019-2028 ($ MILLION)
TABLE 8 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019-2028 ($ MILLION)
FIGURE 1 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 2 KEY BUYING IMPACT ANALYSIS
FIGURE 3 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY PEN INJECTOR, 2019-2028 ($ MILLION)
FIGURE 4 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY AUTO-INJECTOR, 2019-2028 ($ MILLION)
FIGURE 5 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY NEEDLE-FREE INJECTOR, 2019-2028 ($ MILLION)
FIGURE 6 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY PREFILLED, 2019-2028 ($ MILLION)
FIGURE 7 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY SUBCUTANEOUS, 2019-2028 ($ MILLION)
FIGURE 8 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY INTRAMUSCULAR, 2019-2028 ($ MILLION)
FIGURE 9 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY INTRAVENOUS, 2019-2028 ($ MILLION)
FIGURE 10 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY OTHER ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)
FIGURE 11 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY CLINICS/ PHYSICIAN OFFICES, 2019-2028 ($ MILLION)
FIGURE 12 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY AMBULATORY CARE, 2019-2028 ($ MILLION)
FIGURE 13 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY HOSPITAL, 2019-2028 ($ MILLION)
FIGURE 14 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY HOME-BASED, 2019-2028 ($ MILLION)
FIGURE 15 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY OTHER END-USER, 2019-2028 ($ MILLION)
FIGURE 16 JAPAN INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 17 CHINA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 18 AUSTRALIA & NEW ZEALAND INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 19 INDIA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 20 SOUTH KOREA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 21 ASEAN COUNTRIES INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 22 REST OF ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)